TARGETING THE CHK1-STAT3-CIP2A AXIS TO TREAT GLIOBLASTOMA (GBM)

靶向 CHK1-STAT3-CIP2A 轴治疗胶质母细胞瘤 (GBM)

• 批准号: nhmrc : 1090035
• 金额: $ 21.41万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-chk1-stat3-glioblastoma-gbm/519264
• 关键词: TARGETING; CHK1; STAT3; CIP2A; AXIS

Glioblastoma (GBM is a high-grade brain tumour for which current treatments are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified a DNA-damage signalling pathway and demonstrated that perturbation of the pathway significantly reduces tumour growth. We plan to target key proteins of the recently identified pathway and validate these findings using tumour cells directly from GBM patients and relevant animal models of human GBM.

胶质母细胞瘤(GBM)是一种高级别脑瘤，目前的治疗方法不足。肿瘤复发几乎是不可避免的，平均预期寿命是以月为单位衡量的。我们已经确定了一条DNA损伤信号通路，并证明了该通路的扰动显著减少了肿瘤的生长。我们计划针对最近发现的途径的关键蛋白，并直接使用来自GBM患者的肿瘤细胞和相关的人GBM动物模型来验证这些发现。